CONMED Stock | Analysis for May 2026, Price & Rating

CONMED

NYSE:CNMD

$ 36,04

+ $0,07 (0,19%)

36,04 $

+$0,07 (0,19%)

Real-time: 05/13/2026 16:41

CONMED Stock Value

The analyst rating for CONMED is currently Hold.

Hold

CONMED Company Info

EPS Growth 5Y

16,06%

Market Cap

$1,08 B

Long-Term Debt

$0,90 B

Short Interest

3,73%

Quarterly earnings

04/29/2026

Dividend

$0,00

Dividend Yield

0,00%

Founded

1970

Industry

Health Care

Country

United States

ISIN Number

US2074101013

Website

http://www.conmed.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$40,00

11.2%

Last Update: 05/11/2026

Analysts: 5

Highest Price Target $52,00

Average Price Target $40,00

Lowest Price Target $39,00

In the last five quarters, CONMED’s Price Target has fallen from $244,17 to $123,38 - a -49,47% decrease. Six analysts predict that CONMED’s share price will increase in the coming year, reaching $40,00. This would represent an increase of 11,20%.

Top growth stocks in the health care sector (5Y.)

What does CONMED do?

CONMED Corporation (CONMED) is a medical technology company that provides devices and equipment for surgical procedures. The company’s products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Business Strategy The key elements of the company’s strategy include the introduction of new products and product enhancements; pursuing strategic acquisitions; continually revi...

CONMED Corporation (CONMED) is a medical technology company that provides devices and equipment for surgical procedures.

The company’s products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology.

Business Strategy

The key elements of the company’s strategy include the introduction of new products and product enhancements; pursuing strategic acquisitions; continually reviewing its production systems for opportunities to consolidate product lines or process flows, reduce inventory and optimize existing processes; geographic diversification; and active participation in the medical community.

Products

Orthopedic Surgery

The company designs, manufactures, and globally distributes products which enable orthopedic surgeons to surgically address sports medicine injuries in the knee, hip, shoulder and lower extremities. In these procedures, the company offers products, such as BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and Argo Knotless Suture Anchors which provide unique clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries. In addition to implants, the company offers supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. These products include powered resection instruments, as well as fluid management and visualization systems and the related single-use products which are marketed under a number of brands, including CONMED Linvatec, Concept, and Shutt. The company’s product offering for the extremity market includes a portfolio of arthroplasty, biologic, fracture and fixation systems for foot and ankle surgery with products, such as the Quantum Total Ankle System and the CoLink plating system.

The company competes with Smith & Nephew, plc; Arthrex, Inc.; Stryker Corporation; Johnson & Johnson: DePuy Mitek, Inc.; Zimmer Biomet, Inc.; Paragon 28, Inc.; and Treace Medical Concepts, Inc.

The company also provides its customers with a comprehensive line of battery-powered, autoclavable, large and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal and cardiothoracic surgeries. These products are marketed under the Hall surgical brand name, a pioneer in power surgical tools in the United States. In powered instruments, the company’s competition includes Stryker Corporation; Medtronic plc; Johnson & Johnson: DePuy Synthes, Inc.; and Zimmer Biomet, Inc.

In 2024, approximately 77% of orthopedic surgery revenue came from single-use products that are expected to be recurring.

General Surgery

The company’s general surgery product line offers a large range of products in the areas of advanced surgical and advanced endoscopic technologies.

The company’s advanced surgical product offering includes the leading clinical insufflation system (AirSeal). AirSeal includes the proprietary valveless access ports that deliver significant benefits to traditional minimally invasive surgery and robotic surgical procedures. The Buffalo Filter acquisition complemented the CONMED portfolio of smoke removal devices, which provides CONMED with the broadest portfolio of single-use and capital smoke evacuation products available in the medical device market today. In addition to AirSeal and the Buffalo Filter products, the company manufactures and sells an extensive energy line and a broad offering of endomechanical products. The electrosurgical offering consists of monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. The company’s endomechanical products offer a full line of instruments, including the Anchor line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors and dissectors, used in minimally invasive surgery.

The company’s competition includes Medtronic plc; Johnson & Johnson: Ethicon Endo-Surgery, Inc.; Stryker Endoscopy; Olympus Corporation; ERBE Elektromedizin GmbH; and Applied Medical Resources Corporation.

The company’s advanced endoscopic technologies offering includes a comprehensive line of therapeutic and diagnostic products used in gastroenterology procedures which utilize flexible endoscopes, as well as patient monitoring products. In addition to these offerings, the company offers a unique energy platform specifically designed for gastroenterology and pulmonology procedures. Devices include products for dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring. Patient monitoring includes ECG electrodes, EEG electrodes and cardiac defibrillation pads.

The company’s competition includes Boston Scientific Corporation - Endoscopy; Cook Medical, Inc.; Merit Medical Endotek; Olympus Corporation; STERIS Corporation - U.S. Endoscopy; Cantel Medical- Medivators, Inc.; Cardinal Health Inc.; and 3M Company.

In 2024, approximately 91% of general surgery revenue came from single-use products that are expected to be recurring.

International

Expanding the company’s international presence is an important component of its long-term growth plan. The company’s products are sold in over 100 countries. International sales efforts are coordinated through local country dealers (including sub-distributors or sales agents) or through direct in-country sales. The company distributes its products through sales subsidiaries and branches with offices located in Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Italy, Japan, Korea, the Netherlands, Poland, Spain, Sweden and the United Kingdom. In these countries, the company’s sales are amounted to approximately 32% of its consolidated net sales in 2024. In the remaining countries where the company’s products are sold through independent distributors.

Marketing

A significant portion of the company’s products are distributed domestically directly to more than 6,000 hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors.

A significant portion of the company’s the U.S. sales are to customers affiliated with GPOs, IDNs, and other large national or regional accounts, as well as to the Veterans Administration and other hospitals operated by the Federal government. For hospital inventory management purposes, some of the company’s customers prefer to purchase its products through independent third-party medical device distributors.

The company’s employee sales representatives are extensively trained in its various product offerings. Each employee sales representative is assigned a defined geographic area and compensated on a commission basis or through a combination of salary and commission. The sales force is supervised and supported by either area directors or district managers. In certain geographies, sales agent groups are used in the United States to sell the company’s orthopedic products. These sales agent groups are paid a commission for sales made to customers while home office sales and marketing management provide the overall direction and training for marketing and positioning of the company’s products. The company’s sales professionals provide surgeons and other healthcare professionals with information relating to the technical features and benefits of its products.

The company’s healthcare systems organization is responsible for interacting with large regional and national accounts (e.g. GPOs, IDNs, etc.). The company has contracts with many such organizations. The company sells to a diversified base of customers around the world.

Intellectual Property

The company has the rights to intellectual property, including the United States patents and foreign equivalent patents, which cover a wide range of its products with expiration dates from 2025 to 2043. The company owns a majority of these patents and has exclusive and non-exclusive licensing rights to the remainder.

Government Regulation and Quality Systems

The development, manufacture, sale and distribution of the company’s products are subject to regulation by numerous agencies and legislative bodies, including the U.S. Food and Drug Administration (‘FDA’) and comparable foreign counterparts. In the United States, these regulations were enacted under the Medical Device Amendments of 1976 to the Federal Food, Drug and Cosmetic Act and its subsequent amendments, and the regulations issued or proposed thereunder.

The FDA’s Quality System Regulations set forth requirements for the company’s product design and manufacturing processes, require the maintenance of certain records, provide for on-site inspection of its facilities and continuing review by the FDA. Many of the company’s products are also subject to industry-defined standards. Authorization to commercially market the company’s products in the U.S. is granted by the FDA under a procedure referred to as a 510(k) pre-market notification and clearance or Premarket Approval (‘PMA’). The company’s products and processes presently meet applicable standards in all material respects.

Many of the regulations applicable to the company’s devices and products in these countries are similar to those of the FDA.

Requirements pertaining to the company’s products vary widely from country to country, ranging from simple product registrations to detailed submissions, such as those required by the FDA.

The company’s facilities are subject to periodic inspection by the United States Food and Drug Administration (‘FDA’) and foreign regulatory agencies or notified bodies for, among other things, conformance to Quality System Regulation and Current Good Manufacturing Practice (‘CGMP’) requirements and foreign or international standards.

Research and Development

Amounts expended for the company research and development were approximately $54.4 million during 2024.

History

CONMED Corporation was founded in 1970. The company was incorporated under the laws of the state of New York in 1970 by Eugene R. Corasanti and became a Delaware corporation in 2020.

CONMED Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**medical technology:** 60% **surgical instruments:** 30% **orthopedics:** 10% **usa:** 50% **europe:** 30% **asia-pacific:** 20% conmed corporation generates the majority of its revenues from the medical technology sector, followed by surgical instruments and orthopedics. the usa repr...

At which locations are the company’s products manufactured?

**production sites:** usa, mexico, europe conmed corporation mainly produces its medical devices and products in the usa and mexico. additionally, the company also has production facilities in europe to efficiently serve its international markets. this geographical diversification enables conmed to...

What strategy does CONMED pursue for future growth?

**revenue growth:** 8.5% (2025) **r&d investments:** 10% of revenue (2025) conmed corporation pursues a growth strategy that heavily relies on innovation and expansion into new markets. the company consistently invests in research and development to broaden its product range and leverage techno...

Which raw materials are imported and from which countries?

**main raw materials:** stainless steel, plastics, electronic components **main importing countries:** china, germany, japan conmed corporation imports a variety of raw materials and materials needed for the production of their medical devices and surgical instruments. stainless steel and various...

How strong is the company’s competitive advantage?

**market share:** 5% in the global medical technology market (estimated 2026) **r&d expenses:** 7% of revenue (2025) **gross margin:** 55% (2025) conmed corporation has a moderate competitive advantage in the medical technology sector. the company benefits from a solid gross margin of 55%,...

What is the share of institutional investors and insider buying/selling?

**institutional investor share:** approximately 95% (2026, estimated based on historical data) **insider buys/sells:** no significant transactions in the last 12 months (estimated, 2026) the institutional investor share at conmed corporation is traditionally high, indicating the trust of large inv...

What percentage market share does CONMED have?

**market share of conmed corporation:** 5% (estimated, 2026) **top competitors and their market shares:** 1. **medtronic plc:** 15% 2. **stryker corporation:** 12% 3. **johnson & johnson (medtech):** 10% 4. **zimmer biomet holdings, inc.:** 8% 5. **smith & nephew plc:** 7% 6. **becton, dick...

Is CONMED stock currently a good investment?

**revenue growth:** 8.5% (2025) **profit growth:** 10.2% (2025) **r&d expenses:** 7% of revenue (2025) conmed corporation achieved a revenue growth of 8.5% in 2025, indicating strong demand for its medical devices and services. the company also saw a profit growth of 10.2%, attributed to effici...

Does CONMED pay a dividend – and how reliable is the payout?

**dividend yield:** 0.8% (estimated for 2026) **dividend history:** regular payouts for several years conmed corporation regularly pays dividends to its shareholders. the dividend yield is currently around 0.8%, which is relatively low compared to other companies in the industry. the reliabi...

New support ticket

Explore

CONMED Stock Value

CONMED Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does CONMED do?

CONMED Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

CONMED Stock Value

CONMED Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does CONMED do?

CONMED Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.